الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
In summary, aggressive and often temporary use of insulin therapy at disease onset in type 2 diabetes is associated with effective glycemic control with minimal weight gain and hypoglycemia. Early restitution of physiologic insulin secretion and glycemic control could be, in theory, followed by therapies to prolong maintenance of euglycemia, such as thiazolidinediones-(110) or glucagon’s-like peptide 1–based interventions (to date not clinically tested). A more timely and selective introduction of insulin replacement therapy, as β-cell function progresses, could facilitate the achievement and maintenance of euglycemia and thus reduce disease-associated complications